Alternating chemo regimens for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have borderline resectable pancreatic ductal adenocarcinoma (a type of pancreatic cancer that is just barely removable by surgery).
- You have not had chemotherapy or radiation for pancreatic cancer before.
- You are in good enough health to be up and about (ECOG 0 or 1).
- You don’t have certain genetic mutations (BRCA1, BRCA2, PALB2, or DPYD poor metabolizer) that would make standard chemo less safe or less effective.
- Your blood counts and kidney/liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests a combination of chemotherapy drugs (FOLFIRINOX and gemcitabine plus TAMP) given before surgery for borderline resectable pancreatic cancer. The goal is to shrink the tumor and make surgery more successful.
This study tests whether tailoring chemotherapy drugs to your tumor's genetic signature helps treat borderline resectable pancreatic cancer (a type that sits between operable and inoperable). You'll receive chemotherapy before surgery, and the combination used will depend on specific markers found in your tumor.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests a new combination of radiation, chemotherapy, an immunotherapy drug (PD-1 inhibitor), and a medicine that boosts the immune system (thymalfasin) for people with pancreatic cancer that is just on the edge of being removable by surgery. The goal is to see if this treatment can shrink the tumor enough to make surgery possible.
Hear when a new Pancreas Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.